Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia

Not Applicable

Completed

• Conditions: Waldenström Macroglobulinemia
• Interventions: Biological: Blood or bone marrow samples

• Registration Number: NCT02640287
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Waldenström's macroglobulinemia is a rare disease whose pathophysiology remains at present poorly understood, although a recurrent mutation (L265P MYD88) has recently been described. Unlike other lymphoproliferative disorders, there is a defect in isotype switching, mechanism involving AID and NHEJ complex. Using a two-dimensional electrophoresis technology, our group showed that MW had a specific proteomic profile, and one of the differentially expressed proteins is Ku70 (encoded by XRCC6 belonging to NHEJ complex) .

The investigators purpose to explore the mechanisms of underexpression of Ku70/XRCC6 (genetic or epigenetic modification) in comparison with other lymphoid malignancies and normal B cells.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-12-22
• Study First Submitted QC: 2015-12-24
• Study First Posted: 2015-12-28
• Study Start: 2016-02
• Primary Completion: 2020-06-01
• Study Completion: 2020-07-01
• Status Verified: 2021-08
• Last Update Submitted: 2021-08-01
• Last Update Posted: 2021-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• Patient over 18 years, affiliated to the social regimen
• Written consent collected

MW group :

• Patient with a diagnosis of MW according to WHO criteria (based on the results of serum protein electrophoresis, bone marrow analysis with immunophenotyping, cytogenetic analysis and mutation L265P MyD88)

Other SLP :

• Patient with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma

Healthy volunteers :

• volunteers without blood disorders

Exclusion Criteria

• Women of childbearing age who do not have an effective means of contraception
• Pregnant or nursing
• Demonstration of a kappa or lambda monotype on B lymphocytes
• healthy volunteer with B-cell malignancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Healthy subjects	Blood or bone marrow samples	Control healthy subjects without B-cell malignancy
Waldenström macroglobulinemia	Blood or bone marrow samples	Patients with diagnosis of Waldenström macroglobulinemia
Others B-cell malignancies	Blood or bone marrow samples	Patients with diagnosis of Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma or Multiple Myeloma

Primary Outcome Measures

Name	Time	Method
Measure of ratio Ku70/XRCC6	Baseline	Comparing the average level of expression of Ku70 in B cells measured in patients of WM, in patients other SLP and in healthy subjects (without MW and other SLP) , matched for age ( +/- 5 years) and sex

Trial Locations

Locations (1)

CHRU Nancy; 🇫🇷 Vandoeuvre les Nancy, France